ScripDr Reddy’s Laboratories is betting big on the upcoming opportunity for semaglutide in markets like Canada, even as a crucial court case pertaining to Novo Nordisk’s GLP-1 agonist plays out in India. D
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis, Matchpoint Will Seek Out Oral
ScripRoche’s recent Phase III failure for its anti-ST2 monoclonal antibody, astegolimab, in chronic obstructive pulmonary disease (COPD) is a blow not just for the firm but also for the fledgling drug clas
ScripAstraZeneca is the latest large pharma company to announce a major manufacturing investment in the US as the Trump administration threatens to slap tariffs on imports. The drugmaker said July 21 that